3 market-beating ASX ETFs for large-, mid-, and small-cap exposure
These three market-beating ASX ETFs could be excellent picks for the long term if they’re able to the beat the ASX.
Avoid this overpriced ASX healthcare company
Narrow-moat Fisher & Paykel’s FPH first-half fiscal 2025 revenue grew strongly, up 17% to NZD 951 million, while net profit after tax rose 51% to NZD 153 million, both largely tracking our ...
ASX200 hits fresh record closing high of 8444.3 points
The Australian sharemarket cracked fresh records on Thursday, with the big banks and healthcare giants propelling the bourse ...
Insider Transaction: Michael J Farrell Sells $499K Worth Of ResMed Shares
It was reported on November 27, that Michael J Farrell, Chief Executive Officer at ResMed RMD executed a significant insider ...
Insider Activity Spotlight: Michael J Farrell Acquires In ResMed Stock Options
What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Farrell, Chief Executive Officer at ResMed, acquired stock options for 33,036 shares of RMD. These ...
Future Market Insights20h
Global Acoustic Respiration Sensors Market Set for Remarkable Growth, Reaching USD 468.9 Million by 2033
Recent Developments by Key Players: Major players in the respiration rate monitors market are GE Healthcare, Siemens ...
Fisher & Paykel’s Long-Term Trajectory Is Intact
Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...
ResMed CEO’s Stock Transactions and Options Activity
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update.Don't Miss our Black Friday ...